Cancer cells showing microsatellite instability (MSI) demonstrate a high frequency of acquired frameshift mutations that result in the generation of nonsense mutations. RNA transcripts carrying these nonsense mutations are usually targeted for degradation through the nonsense mediated decay (NMD) pathway. Blocking this pathway with drugs such as emitine, results in the 'stabilization' of these mutant transcripts, which can now be detected on cDNA arrays. Unfortunately, emetine also induces a stress response that results in upregulation of additional transcripts which contribute to the analysis of the array. As a result, identifying which genes truly carry nonsense mutations is made more difficult. To overcome this, we have combined the emetine treatment with actinomycin D, which effectively prevents the upregulation of stress response genes while still stabilizing mutant transcripts. When we applied this modified approach to the analysis of MSI-positive colon cancer cells, we identified mutations in the UVRAG and p300 genes.
Introduction
The development of cancer is widely believed to result from the activation of oncogenes and the inactivation of tumor-suppressor genes (TSGs), in many cases in the same cancer (Cowell, 2002) . Despite major successes in cloning TSGs related to hereditary forms of various cancers, it is now clear that the majority of the more common sporadic types of these tumors do not frequently show inactivation of these genes. The development of cancer, therefore, is likely to require the acquisition of inactivating mutations in a number of as yet unidentified different genes and pathways during the development and progression of the tumor. Although it is widely believed that TSGs are central to this process, still very few have been identified. It was shown 20 years ago that the cancer cell genome can reorganize in a variety of ways to 'expose' recessive mutations in critical genes (Cavenee et al., 1983) . This reorganization results in the so-called loss of heterozygosity (LOH) in the tumors, which has been generally believed to fulfill the predictions of the Knudson two-hit hypothesis through the homozygous loss of gene function (Knudson, 1971 (Knudson, , 1984 . Since then, LOH has been one of the most intensively investigated phenomenon in cancer cells and LOH maps for most of the common cancers have now been well described. Despite this information, there have still been relatively few genes which have been isolated as true TSGs based on the observation of LOH alone.
Studies of the TSGs that have been identified have demonstrated that one of the more common ways that they are inactivated is through the acquisition of nonsense mutations that generate premature translation termination codons (PTC). In the retinoblastoma gene, for example, these occur as a result of either singlenucleotide changes or frameshift mutations as a result of insertions and deletions. It has been reported that the mRNA that contains these nonsense or frameshift mutations have decreased stability (Kratzke et al., 1994; Jiang et al., 1997) . It is now known that these mutant mRNAs are rapidly degraded through a mechanism known as nonsense mediated decay (NMD) (Losson and Lacroute, 1979; Culbertson, 1999; Frischmeyer and Dietz, 1999) .
NMD is a complicated system, but is mediated through the assembly of protein complexes derived from genes such as those of the Upf family, which can recognize mRNAs which carry PTCs. It has been suggested that during the splicing process of the premRNA, the exon/exon boundaries in the processed mRNA are marked in some way with a tag which is removed only during the first round of translation. When a pre-mRNA that contains a PTC is processed, translation will stop at this codon and all tags distal to this point are retained on the mRNA. These tags then act as the signal to recruit the Upf protein complex that results in the degradation of the mRNA (Ishigaki et al., 2001) . In our previous analysis of mRNA species in patients heterozygous for nonsense mutations in the RBI gene, we were never able to identify the mutant RNA in the presence of the normal one using RT-PCR (Kratzke et al., 1994) , demonstrating that NMD can be a very rapid process. The only exception to the rule is when the PTC occurs within the last exon, since the NMD complex in this case cannot distinguish the mutant mRNA from the normal one because all of the exon/ exon juntion tags will have been removed by that time (Li and Wilkinson, 1998; Hentze and Kulozik, 1999; Sun and Maquat, 2000) .
Blocking translation with specific drugs, such as emetine, has been shown to abrogate the NMDmediated degradation of mutant mRNA (Belgrader et al., 1993; Ishigaki et al., 2001) . Inhibition of NMD, therefore, effectively results in an increased amount of the mutant mRNA in the cells. In any given tumor, therefore, it should be possible to identify mRNA transcripts which contain PTCs with a realistic expectation that they have a tumor-suppressor function. Recently, a strategy, named 'gene identification by NMD inhibition' (GINI), was proposed for the identification of genes containing nonsense mutations (Noensie and Dietz, 2001) . GINI was tested using colon cancer and Sandhoff (SD) disease cell lines, which contained previously described nonsense mutations in the MLH1 and hexoaminidase B (HEXB) genes, respectively. Using cDNA microarrays, Noensie and Dietz (2001) demonstrated that treating the cells with the translation-blocking drug emetine resulted in the elevated mRNA levels of about 5% of all genes present on the microarray, which included MLH1 and HEXB.
Despite the proof-of-principle of the GINI strategy, it was clear from the identity of many of the genes which showed increases in mRNA levels that many were induced as the result of a stress response to the drug treatment. We have now extended this procedure to overcome some of these problems and, using a series of microsatellite unstable colon cancer cell lines, we have identified two novel genes which are frequently mutated in these types of colon tumors.
Methods

Cell culture, drug treatment and Western blotting
Colon cancer cell lines were grown in DMEM supplemented with 10% fetal bovine serum and antibiotics. Emetine or actinomycin D treatments were performed in 30 mm tissue culture plates. Emetine (100 mg/ml) was added to the cells 10 h before RNA extraction. In the case of emetine and actinomycin D treatment, emetine (100 mg/ml) and actinomycin D (2 mg/ ml) were added to the cells 4 h before RNA extraction. For Western analysis of p300 expression, nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction reagents (PIERCE). Protein concentration was measured using BioRad dye-binding assays and 20 mg of nuclear extracts were run on 8% SDS-PAGE. The separated proteins were transferred onto PVDF membranes (Immobilon P; Millipore, Bedford, MA, USA), blocked with skim milk and incubated with anti-N-terminal anti-p300 (Santa Cruz, CA, USA) for 2 h at room temperature. Antigen-antibody complexes were detected using a secondary anti-rabbit antibody, followed by enhanced chemiluminescence.
RNA isolation and northern blot
Total RNAs for microarray and Northern blot analysis were prepared with TRIZOL reagents (Invitrogen, CA, USA). For Northern blots, 10 mg of total RNA was separated on 1.2% agarose formaldehyde gels, and transferred to a nylon membrane (Hybond-N þ , Amersham, Boston, MA, USA). Hybridizations with radiolabeled probes were carried out at 681C using Express Hyb Hybridization solution (Clontech, Palo Alto, CA, USA). Radioactivity was detected by autoradiography. Radiolabelled probes were generated by PCR of RNA-derived cDNA.
Microarray analysis
The cancer-specific arrays that contain genes selected for their reported involvement in the cancer process (http://microarrays.roswellpark.org) used in this experiment were produced at the RPCI Microarray and Genomics Core Facility. cDNA labeling and hybridizations to the arrays was performed by the RPCI Microarray and Genomics Core Facility. All expression data were analysed using the Microsoft Excel program.
P300 and UVRAG mutational analysis
Exons of the P300 and UVRAG genes were PCR amplified from genomic DNA of cell lines using primers complementary to intron sequences flanking the exon, and the PCR products were sequenced using an ABI PRISM Sequencer in the RPCI core facility.
RT-PCR
Total RNA from LS180 cells was prepared at different times of the drug treatment with TRIZOL reagent (Invitrogen, CA, USA) and cDNAs were synthesized using the ThermoScript RT-PCR system (Invitrogen, CA, USA). Primer sequences for the PCR amplification of cytochrome P450, TGFbRII and G3PDH DNA sequences are available upon request.
Results
The GINI strategy identifies genes carrying novel PTCs, which would normally result in the rapid degradation of the mutant mRNA. One major mutational mechanism that results in these PTCs is through insertion/deletion of one, or a few, nucleotides within mononucleotide stretches which are located within the coding regions of the genes. Owing to the inability of tumors with defects in the mismatch repair process to correct these errors, these are very common types of mutation in cancers with MSI (Ionov et al., 1993; Markowitz et al., 1995) , where the resultant frameshifts invariably result in the generation of downstream stop codons. Since this observation suggests that microsatellite instability (MSI) þ cancers should show a large number of nonsense mutations in critical cancer genes, we applied the GINI strategy, using emetine to block NMD, to a variety of colorectal cancer cell lines with MSI.
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Analysis of mRNA changes in colon cancer cell lines following emetine treatment
To test the effect of emetine treatment on the degradation of frameshift mutation-containing mRNAs, we used the MSI þ LS180 colorectal cancer cell line, which has frameshift mutations in an (A) 10 coding repeat in both alleles of the TGFbRII gene (Markowitz et al., 1995) . Northern blot analysis ( Figure 1 ) showed that blocking translation in LS180 cells with emetine indeed resulted in increased levels of TGFbRII mRNA. In contrast, emetine treatment did not increase TGFbRII mRNA in the microsatellite negative (MSIÀ) cell lines SW620 and HT-29 (Figure 1 ), which do not carry a mutation in this gene. Thus, we had independently confirmed the observation that this approach could identify genes with PTCs. To determine the changes in RNA levels as a result of emitine treatment of colon cancer cells, we used a cDNA microarray that contained 2500 genes which had been shown to be related in some way to cancer. When RNA from both the emetinetreated and untreated LS180 cells was used to probe the microarray, we observed that approximately 200 of the 2500 genes on the array had a higher than twofold increase in their mRNA levels as a result of emetine treatment. TGFbRII was among the 10 transcripts showing the highest increase (Table 1) , which demonstrated that these arrays could identify PTC-containing genes.
The large number of transcripts that showed an increase due to the emetine treatment alone, however, made it difficult to determine which of them might carry novel PTC mutations. In an attempt to overcome this problem, we extended our analysis to three other colon cancer cell lines: RKO, which has a high level of MSI, and two MSIÀ cell lines, SW620 and HT29. From these studies, we identified the SMAD4 gene showing a 7.4-fold increase in RNA levels in HT-29, but only an approximate twofold increase in DLD1 and RKO. Sequencing the SMAD4 gene in HT29 identified a C to T substitution at position 931 that resulted in a stop codon which has been previously reported (WoodfordRichens et al., 2001 ). HT29 does not show MSI, which probably accounts for the fact that this mutation was not within a coding microsatellite but still demonstrates that GINI can identify genes with PTCs.
Since genes mutated in MSI þ cells are generally different from those in MSIÀ cells (Kim et al., 1994; Perucho, 1996; Laurent-Puig et al., 1999; Salahshor et al., 1999; Samowitz et al., 2001) , we hypothesized that transcripts that showed an increase in RKO cells, but not in SW620 and HT-29, might be more likely to carry PTC mutations. In RKO cells, over 350 of the 2500 genes on the microarray showed an mRNA increase of twofold or greater. However, the majority of these transcripts were also increased in other cell lines used in the analysis, independent of their MSI status (Table 2) . Among the 30 most highly increased transcripts, the SMAD6 gene was exclusively increased in the RKO cells (Table 2 ). Owing to the observation with SMAD4, we sequenced the SMAD6 cDNA from RKO cells, but did not identify any mutations. We interpret this to mean that, in addition to differences due to MSI status, there are also individual variations between different cell lines in their response to emetine treatment. This suggestion further complicates the process of selecting candidates for mutational analysis. From the identity of many of the genes identified in this comparison of the three cell Figure 1 Stabilization of frameshift-containing transcripts with emetine. Northern blots show the mRNA levels of TGFbRII and G3PDH transcripts in emetine-treated ( þ ) and untreated (À) colon cancer cell lines. The MSI þ cell line LS180, which has a frameshift mutation in both alleles of TGFbIIR , shows a more intense band in the emetine-treated ( þ ) lane. In contrast, MSIÀ HT 29 and SW620 show the same levels of expression following emetine treatment. Low levels of TGFbIIR mRNA are seen in all lanes because NMD still requires the first round of translation before degradation, and so a small amount of the transcript is always present lines, it appeared that they were probably induced as part of a stress response.
Effect of combining emetine treatment with actinomycin D treatment on stress response
The objective of the NMD-blocking experiments was to identify genes which potentially contain PTC. However, the increase in many mRNA transcripts is probably due to a stress response to emetine, which made it difficult to determine which ones were true candidates for sequencing. To reduce the number of candidate genes, therefore, we attempted to eliminate the contribution of the stress genes to the mRNA probe, by blocking both NMD and mRNA synthesis. Microarray analysis of emetine-treated cells showed that the gene encoding cytochrome P450 demonstrated the highest mRNA increase in all cell lines analysed (Tables 1 and 2 ). This gene is well known to be induced by stress to the cells. Sequencing the cDNA of this gene failed to identify mutations in LS180 cells, strongly suggesting that it was, in fact, induced in response to stress. Since the LS180 cells also showed mRNA increases for the TGFbRII gene, due to stabilization of mutant mRNA following NMD inhibition, we used this cell line to determine whether combining the inhibition of NMD with the inhibition of transcription, using actinomycin D (AD), would eliminate the induction of stress response genes without affecting the increase of mutant transcripts. We, therefore, compared the mRNA changes in LS180 cells for the P450, TGFbRII and GAPDH genes, following combined AD and emetine treatment (ADE) versus AD treatment alone. As a control, we analysed the same genes for mRNA changes following emetine treatment alone versus no treatment.
RT-PCR analysis showed that transcription of P450 was only highly induced following emetine treatment alone, and not after treatment with ADE (Figure 2 ). In contrast, the increased level of TGFbRII mRNA was retained following ADE treatment, although the level of the increase was much lower (Figure 2) . The overall decrease in the amount of mRNA in ADE-treated cells is expected because of the generalized reduction in the production of cellular mRNA synthesis. This analysis, therefore, clearly demonstrated that treatment with actinomycin D could significantly block stress-induced mRNA transcription of genes, without interfering with the effect of emetine on the NMD process.
Since the highly MSI þ RKO cells showed the largest number of mRNA increases following emetine treatment (not shown), we decided to use this cell line to compare treatments with ADE and emetine alone. Total RNA from ADE-or AD-treated cells were prepared 4 h after drug treatment and hybridized to the cDNA microarray. The results of this hybridization (Table 3) demonstrated that, despite the inhibition of transcription with actinomycin D, a large number of genes still showed mRNA increases following emetine treatment. However, when we compared the results of the hybridization of ADE-versus AD-treated cells (Table 3) , with that of emetine-treated versus untreated cells (Table 2) , we found that, of the 30 genes that showed the highest mRNA increases following emetine treatment, only two genes, the UV resistance-associated gene (UVRAG) and p300, also showed mRNA increase following ADE treatment. We, therefore, sequenced the cDNAs for both of these genes to determine whether mutations were present.
Mutation analysis of the UVRAG and p300 genes UVRAG showed a 7.5-fold change in RKO cells after emetine treatment alone (Table 2) , and also showed a significant increase following ADE treatment (Table 3) . Bioinformatic analysis of this gene demonstrated that it contains an (A) 10 exonic repeat. When this region was sequenced specifically, we identified a heterozygous deletion of one adenine within this repeat in RKO cells, which generates a downstream stop codon as a result of a frameshift. Similar heterozygous mutations were also found in the MSI þ colorectal cancer cell lines LoVo, HCT116 and LS180. To determine whether this gene was also mutated in MSI þ primary colon tumors, we analysed the same (A) 10 repeat in 11 tumors, and found mutations in two of them. The second gene that showed an increased level of mRNA following both emetine and ADE treatments was p300. P300 is a histone acetyltransferase that regulates transcription via histone acetylation, and is known to acetylate p53 in response to DNA damage (Grossman, 2001) . DNA damage-induced p53 acetylation is thought to stimulate its ability to bind to DNA in a sequence-specific manner, and to enhance its transcription resulting in growth arrest and/or apoptosis. Sequencing the p300 gene using genomic DNA from RKO cells identified two different heterozygous frameshift mutations. One of these mutations was a deletion of an adenosine in an (A) 7 sequence in exon 27 (nucleotides 5601-07 of the p300 cDNA); the other Figure 2 The effect of actinomycin D on the stress response to emetine. LS180 cells were incubated with a combination of emetine (100 mg/ml) and actinomycin D (2 mg/ml) (lanes 4, 6, 8, 10) or with actinomycin D alone (lanes 3, 5, 7, 9) for various times. As a control, the LS180 cells were incubated with emetine only for 10 h (lane 2) or left untreated (lane 1). RT-PCR analysis shows that actinomycin D treatment inhibits the emetine-induced upregulation of cytochrome P450 gene, but not the emetine-mediated increase of the frameshift mutation-containing TGFbIIR. In bold font are the genes that show mRNA increase following emetine only treatment.
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was a deletion of adenosine in an (A) 5 sequence in exon 3 (nucleotides 2070-74). Western blot analysis of the p300 protein in nuclear extract in RKO cells (Figure 3b ) demonstrated that both alleles of the p300 gene had been inactivated by mutations. To determine whether p300 mutations occur frequently in primary colon cancers, we analysed the same microsatellite regions in exon 3 and exon 27 that showed mutations in the RKO cells, in DNA from 25 primary colon cancers with MSI. We identified the same frameshift mutations in the (A) 7 repeat of exon 27 in two primary tumors and an additional deletion at a splicing site of exon 3 in other primary tumors with MSI. The p300 gene is very large, with over 30 exons, and, even though we have not surveyed the whole gene for the presence of mutations, the presence of frameshifts in the coding microsatellites in 10-15% of tumors confirms that the mutations in p300 are not exclusively confined to cell lines.
Discussion
One of the challenges in cancer genetics research continues to be the identification of genes which contribute to the development of the malignant phenotype. Since these genes are likely to be different in tumors from different cell origins, a general strategy that is applicable to mutation detection in all tumors would obviously be an advantage. We believe that the modifications we have made to the GINI strategy provide a more robust approach than the previous one, which should prove useful in the identification of novel TSGs. The principle that TSGs are inactivated as a result of PTCs is now well established but this is not the only mechanism, however. Promoter methylation in some genes is a more common mechanism of inactivation, which will not be detected by GINI. Total gene deletion is another mutation that will not be recognized by GINI. However, in many cases, promoter methylation and deletions are usually only part of the spectrum of mechanisms that inactivate specific TSGs. It is important, therefore, in order to maximize the chances of identifying mutant TSGs, to include sufficient cell lines in the analysis of the microarrays. In this way, the presence of PTCs in one cell line and not another will not be missed. Clearly, using MSI þ cells has the advantage in this approach because of the high frequency of frameshift mutations that are generated because of DNA repair defects in the cells. Other types of tumors that frequently show MSI include gastric, endometrial and stomach and, less frequently, pancreas, prostate, ovarian, breast and cervical, where the GINI approach should prove useful. It is important to note in this respect that it is not the occurrence of a frameshift that is important in these cases, since there must clearly be a selective advantage for a gene mutation for the development of the cancer phenotype. The demonstration that the modified GINI approach can also identify point mutations that generate PTCs, as demonstrated by the discovery of the SMAD4 gene mutation in HT29 cells, clearly demonstrates, however, that this approach can also be applied to the identification of TSGs in MSIÀ cells. The one potential limitation in this approach is that it is more conveniently carried out using tumor cell lines, which may contain mutations in genes which are either unrelated to the malignant phenotype, or which have been acquired as a result of prolonged culture. It is also true, however, that these cell lines were derived from primary tumors, and so they almost certainly still carry the mutant genes which were involved in the development of the primary tumor in the patient. This is clearly shown from our study of the TGFbRII gene, which is known to be frequently mutated in MSI þ colon cancer cells, and this mutation is retained in the cell lines. Final verification of the involvement of any gene in tumorigenesis, however, requires the demonstration that the same gene is mutated in fresh tumors as we have shown here for the UVRAG gene, as well as the p300 gene, and further that these genes affect the malignant phenotype (manuscript in preparation).
Our results clearly show that combining inhibition of NMD with suppression of stress gene transcription using actinomycin D can eliminate stress response genes from the analysis. Analysing only those genes that show mRNA increases following both treatments significantly enhances the chances of identifying mutated genes. There is, however, still a possibility that AD treatment in itself will also induce a stress response, which is why we chose to compare gene expression changes in different cell lines and after different treatments. Although we demonstrated for the first time successful identification of novel mutated genes using GINI, one drawback is that treatment of the cells with actinomycin D resulted in the overall lower amounts of cellular mRNA, which pushes the cDNA array analysis to the limit since it is generally considered that the relevance of changes of twofold or less are hard to interpret since small changes could also be due to background variation. Thus, despite using four times more total RNA for hybridization, almost half of all transcripts still produced undetectable signals on the array which means that we may have missed mutant genes. Clearly, modifying the method of NMD inhibition in such a way that it does not induce stress response will be very important for the development of a robust high throughput technology for the identification of mutated genes. Recently, the small interfering RNA (siRNA) approach to inhibit the expression of the Upfl and Upf2 genes, the specific mediators of NMD, has been shown effectively stabilize the mutant T-cell receptor b transcript in HeLa cells (Mendell et al., 2002) , which could be one approach to minimize stress responses during the suppression of NMD (Lelivelt and Culbertson, 1999) .
The demonstration of mutations in the UVRAG gene in colon cancer was intriguing and is, to our knowledge, the first report of the involvement of this gene in colon cancer. It is intriguing because the mutations were always heterozygous, suggesting an essential role for this gene in cell survival, and possibly that reduced expression levels are important to tumorigenesis. At this time, the true incidence of mutations in this gene is not known, since we only analysed the region containing one coding microsatellite in order to confirm that mutations were also present in primary tumors as well as cell lines. UVRAG, which is ubiquitously expressed, was originally identified through its ability to partially complement the UV sensitivity in xeroderma pigmentosum cells (Teitz et al., 1990) , and apparently localizes either within organelles or is part of the cytoskeleton. Its location in 11q13 places it in a region of the genome frequently implicated in the development of a variety of cancers, and is apparently in an amplicon seen in breast cancer. More recently, UVRAG was one of the genes interrupted by a constitutional inversion in a patient with a left-right axis malformation (Iida et al., 2000) . Despite this, the function of this coiled-coil-containing gene is completely unknown, but clearly merits further investigation because of the potential role in DNA repair and its frequent mutation in colon cancer cells.
In summary, we have identified genes carrying nonsense mutations in colon cancer cell line following manipulation of the NMD pathway. The biallelic inactivation of the p300 gene in the RKO cells and the mutations in fresh tumors suggest the functional significance of the p300 gene inactivation for the progression of tumors with MSI.
